AstraZeneca results: 9M and Q3 2026
AstraZeneca PLC AZN
News
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
AstraZeneca, Daiichi Sankyo Drug Gets EU Nod in Early-Stage Breast Cancer
AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca Adds New Indication for Ultomiris Drug in Rare Kidney Disease
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
AstraZeneca Partners With Oracle to Refine Clinical Research With AI
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
Flu season is already here. Here's what to know about this year's flu shots.
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
United States